5 results
This study is designed as a proof-of-concept to assess if inhibition of IL-1* by canakinumabwill improve lung function in association with attenuation of tissue inflammation in patientswith chronic sarcoidosis, therefore allowing further development…
Primary:To evaluate if the proportion of patients in clinical remission on canakinumab 4mg/kg (+/- concomitant NSAID only) who are able toremain on a reduced canakinumab dose (2mg/kg every 4 weeks) or prolonged canakinumab dose interval (4mg/kg…
To demonstrate the safety, performance and effectiveness of the EMPOWER* Modular Pacing System (MPS), as well as the EMPOWER and EMBLEM* Subcutaneous ICD Coordinated System. Additionally, data from this study may be used to support pre-market and…
2.1 Primary The primary objective of the study is to evaluate the efficacy of troriluzole as adjunctive therapy compared to placebo in subjects with OCD who have had an inadequate response to their current OCD treatment based on the change in their…
The primary objective of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with OCD who have had an inadequate response to standard of care (SOC) treatment for OCD and as defined in the…